Mexico City, Mexico - On July 30, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") received the approval for registration of the independently developed Firefighter™ PTCA Balloon Catheter ("Firefighter™") in Mexico from the Mexican authority of COFEPRIS on top of the CE certification and CFDA registration approval. It has also been granted marketing certificates in Brazil, Argentina, Korea and India successively.
Firefighter™ is a rapid exchange PTCA Balloon Catheter, which can be used for the dilatation of coronary artery stenosis lesions to improve myocardial perfusion, and for the pre-dilatation of the lesions prior to the implantation of stents. It can be used in combination with Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), which was also independently developed by MicroPort®. Firefighter™ has relatively lower profile than that of its competitors of the same size, and is made of flexible materials, enabling the product to cross stenosis and tortuous lesions multiple times. Its design size allows the 5F guiding catheter to accommodate two Firefighter™ balloon catheters, so as to facilitate the complex techniques such as kissing balloon inflation. A total of 43 sizes with 12 diameters (1.0mm-4.0mm) and four lengths (6mm, 10mm, 15mm and 20mm) are covered by the registration approval for Firefighter™ in Mexico.
Previously, MicroPort® had gained the registration approvals for Firehawk®, Firebird2® Rapamycin-Eluting Coronary CoCr Stent System, FOXTROT™ PRO PTCA Balloon Catheter and FOXTROT™ NC PTCA Balloon Catheter in Mexico. MicroPort® International Business First Vice-President Dr. Linda Yingqing Lin said, "The registration approval for Firefighter™ has further widened the product line of MicroPort® in Mexico, tremendously driving the consolidation and growth of the market share of the company’s cardiovascular products in South America. In future, MicroPort® will commit itself to introduce more high-end medical device products of good quality and high affordability to the local market, so as to benefit more patients."